Brief Report on Companies Making the Right Moves for Growth and Special "Tech Boom" Profile

New York, NY January 21th, 2015 - SmallCapIR.com initiates coverage on Nxt-ID Inc. (NASDAQ: NXTD)

Could this be the home run of all home runs?

Now introducing the Wocket smart wallet check out the video here http://wocketwallet.com/

Although the Wocket in our opinion is superior to any other secure wallet on the market. Do not get hung up on this as the only application for their proprietary technology.

My question is, could this be incorporated in to the next generation I-phone and Android devices? If we are right this could be a home run beyond all home runs. Not to mention the other endless possibilities here. See website for current peripheral applications here: http://3d-id.net/

The company’s solutions are based upon its Match-Bio™ platform, a real-time, dynamic, multi-factor biometric authorization technology.  The Match-Bio™ platform uses physical attributes that are unique to each user, such as their voice, fingerprints, face, and retinas.  These physical attributes are combined with unique attributes of users’ accounts or devices to create a security solution.  The company’s Mobile-Bio™ platform contains multiple proprietary, next generation security technologies.  The platform enables the company to produce a range of innovative products incorporating their proprietary methods.  Each of these products can then be targeted at different applications and market segments.

Nxt-ID, Inc. (NASDAQ: NXTD) is an early stage technology company focused on providing biometric products, solutions, and services for applications that have a need for biometric secure access control.  The company was founded in 2011 and is headquartered in Shelton Connecticut. The company introduced its first commercial product at the 2015 Consumer Electronics Show in Las Vegas, where it was named as one of “11 Hot Products at CES” by Wired.com.

Full Profile Here:
could-we-be-sitting-on-the-next-smart-phone-tech?

CapRock Research has also initiated coverage with an overweight/buy recommendation and $4.80 Near Term Price Target. CapRock Research full report:
NXTD-Analyst-Report

Other stocks on watch this week
Sycamore Entertainment Group, Inc. (OTCBB: SEGI) is a diversified entertainment company that specializes in the acquisition, marketing and worldwide distribution of quality finished feature-length motion pictures. Sycamore's management team utilizes its long standing relationships to provide market specific publicity, promotion, media buying, theatrical placement and Print & Advertising financing for theatrical domestic release.

The company has signed a distribution agreement for a film directed by former NFL star. Read about this film and the distribution agreement in this report: http://bit.ly/-SEGI-AnalystReport

Oncologix Tech, Inc. (OTCBB: OCLG) operates and manufactures Class II medical device products, delivers Personal Healthcare Services, and Home Medical and Durable Medical products nationally. For its clients, Oncologix provides FDA approved medical devices, state licensed healthcare services and medical product distribution.

Read about the company’s financial results in the report offered at the following link: http://bit.ly/-OCLG-AnalystReport

Herborium Group, Inc. (OTCBB: HBRM) is a novel botanical therapeutics company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.

The report that follows looks at the HBRM business model and discusses revenue growth in some of its business sectors: http://bit.ly/-HBRM-AnalystReport

Advanced Medical Isotope Corp. (OTCBB: ADMD) is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.

The report you will find at the link details the company’s interaction with the FDA on one of its patented medical devices: http://bit.ly/-ADMD-AnalystReport

About Small Cap IR
We make the connection between sophisticated investors and high quality small cap companies. An issuer of reports written by chartered financial analysts (CFA’s) who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

For more information and services provided beyond this release please use contact information provided below.

Forward-Looking Disclaimer   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Compliance Procedure   
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at [e-mail]. For any urgent concerns or inquiries please contact us at [e-mail].
Source: Small Cap IR
Contact: [e-mail]